The BEST-BE observational study will track 1,000 bronchiectasis patients to measure the impact of brensocatib on pulmonary exacerbations and patient quality of life.
RT’s Three Key Takeaways:
- Real-World Evidence: The BEST-BE study will monitor 1,000 adults with non-cystic fibrosis bronchiectasis over two years to evaluate the effectiveness and safety of brensocatib in clinical practice.
- Diverse Patient Population: Researchers will collect data from a broad group of participants, including those with nontuberculous mycobacterial lung infections and immunocompromised individuals, to build on previous clinical trial findings.
- Advanced Research Tools: The study will utilize CRISPR-based detection, AI-assisted imaging analysis, and sputum rheology to better understand disease progression and treatment response.
The Bronchiectasis and NTM Association is collaborating with Insmed on a multicenter, prospective study to evaluate the real-world effectiveness, safety, and tolerability of brensocatib (Brinsupri) in adult patients with non-cystic fibrosis (non-CF) bronchiectasis, according to a news release.
The Brensocatib Effectiveness, Safety, and Tolerability in Bronchiectasis (BEST-BE) observational study is designed to measure the incidence and frequency of pulmonary exacerbations, or episodes of sudden worsening of respiratory symptoms, in adults 18 to 85 years old. The participants will be observed over a two-year period across 13 US sites.
In addition to exacerbations, the study will track changes in health-related quality of life and the frequency of adverse events. To expand on the evidence base for brensocatib following the Phase 3 ASPEN study, the BEST-BE study will include a diverse population of participants, including those with concurrent nontuberculous mycobacterial (NTM) lung infections and immunocompromised individuals.
“The Bronchiectasis and NTM Association is excited to conduct the BEST-BE study, which will follow diverse patient populations to see the long-term efficacy and safety profile of brensocatib, and how it affects disease progression in a real-world setting,” said Charles L Daley, of National Jewish Health and chief research officer of the Bronchiectasis and NTM Association, in a news release. “This additional evidence could further shape clinical practice and help clinicians make informed treatment decisions for their patients with bronchiectasis.”
The study will also incorporate technologies such as CRISPR-based detection of Mycobacterium avium complex, AI-assisted CT scan analysis, and sputum rheology assessments. The research team will also establish a biobank to support future studies.
“Bronchiectasis is one of the most complex conditions in pulmonary medicine. The BEST-BE study is designed to continue to deepen our understanding of how brensocatib works for the full range of patients with non-CF bronchiectasis who need it most, and the Bronchiectasis and NTM Association is well positioned to lead this effort,” said Martina Flammer, chief medical officer of Insmed, in a news release.
